239 related articles for article (PubMed ID: 25304374)
21. Aldo-keto reductase family 1 B10 affects fatty acid synthesis by regulating the stability of acetyl-CoA carboxylase-alpha in breast cancer cells.
Ma J; Yan R; Zu X; Cheng JM; Rao K; Liao DF; Cao D
J Biol Chem; 2008 Feb; 283(6):3418-3423. PubMed ID: 18056116
[TBL] [Abstract][Full Text] [Related]
22. E-cadherin expression in obesity-associated, Kras-initiated pancreatic ductal adenocarcinoma in mice.
Stark AP; Chang HH; Jung X; Moro A; Hertzer K; Xu M; Schmidt A; Hines OJ; Eibl G
Surgery; 2015 Dec; 158(6):1564-72. PubMed ID: 26297056
[TBL] [Abstract][Full Text] [Related]
23. Aldo-keto Reductase 1B10 Restrains Cell Migration, Invasion, and Adhesion of Gastric Cancer via Regulating Integrin Subunit Alpha 5.
Yao H; Hu J; Shao Y; Shah Q; Zheng S
Turk J Gastroenterol; 2023 Dec; 34(12):1197-1205. PubMed ID: 37823316
[TBL] [Abstract][Full Text] [Related]
24. Targeting the K-Ras--JNK axis eliminates cancer stem-like cells and prevents pancreatic tumor formation.
Okada M; Shibuya K; Sato A; Seino S; Suzuki S; Seino M; Kitanaka C
Oncotarget; 2014 Jul; 5(13):5100-12. PubMed ID: 24947996
[TBL] [Abstract][Full Text] [Related]
25. Involvement of the aldo-keto reductase, AKR1B10, in mitomycin-c resistance through reactive oxygen species-dependent mechanisms.
Matsunaga T; Yamane Y; Iida K; Endo S; Banno Y; El-Kabbani O; Hara A
Anticancer Drugs; 2011 Jun; 22(5):402-8. PubMed ID: 21317765
[TBL] [Abstract][Full Text] [Related]
26. A human cancer xenograft model utilizing normal pancreatic duct epithelial cells conditionally transformed with defined oncogenes.
Inagawa Y; Yamada K; Yugawa T; Ohno S; Hiraoka N; Esaki M; Shibata T; Aoki K; Saya H; Kiyono T
Carcinogenesis; 2014 Aug; 35(8):1840-6. PubMed ID: 24858378
[TBL] [Abstract][Full Text] [Related]
27. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
[TBL] [Abstract][Full Text] [Related]
28. miR-216b suppresses tumor growth and invasion by targeting KRAS in nasopharyngeal carcinoma.
Deng M; Tang H; Zhou Y; Zhou M; Xiong W; Zheng Y; Ye Q; Zeng X; Liao Q; Guo X; Li X; Ma J; Li G
J Cell Sci; 2011 Sep; 124(Pt 17):2997-3005. PubMed ID: 21878506
[TBL] [Abstract][Full Text] [Related]
29. Epidermal growth factor down-regulates the expression of neutrophil gelatinase-associated lipocalin (NGAL) through E-cadherin in pancreatic cancer cells.
Tong Z; Chakraborty S; Sung B; Koolwal P; Kaur S; Aggarwal BB; Mani SA; Bresalier RS; Batra SK; Guha S
Cancer; 2011 Jun; 117(11):2408-18. PubMed ID: 24048788
[TBL] [Abstract][Full Text] [Related]
30. Insulin promotes invasion and migration of KRAS
Wang G; Yin L; Peng Y; Gao Y; Gao H; Zhang J; Lv N; Miao Y; Lu Z
Cell Prolif; 2019 May; 52(3):e12575. PubMed ID: 30838710
[TBL] [Abstract][Full Text] [Related]
31. CBX7 suppresses urinary bladder cancer progression via modulating AKR1B10-ERK signaling.
Huang Z; Yan Y; Zhu Z; Liu J; He X; Dalangood S; Li M; Tan M; Cai J; Tang P; Huang R; Shen B; Yan J
Cell Death Dis; 2021 May; 12(6):537. PubMed ID: 34035231
[TBL] [Abstract][Full Text] [Related]
32. Mutant KRAS is a druggable target for pancreatic cancer.
Zorde Khvalevsky E; Gabai R; Rachmut IH; Horwitz E; Brunschwig Z; Orbach A; Shemi A; Golan T; Domb AJ; Yavin E; Giladi H; Rivkin L; Simerzin A; Eliakim R; Khalaileh A; Hubert A; Lahav M; Kopelman Y; Goldin E; Dancour A; Hants Y; Arbel-Alon S; Abramovitch R; Shemi A; Galun E
Proc Natl Acad Sci U S A; 2013 Dec; 110(51):20723-8. PubMed ID: 24297898
[TBL] [Abstract][Full Text] [Related]
33. c-Met targeting enhances the effect of irradiation and chemical agents against malignant colon cells harboring a KRAS mutation.
Li Y; Wang J; Gao X; Han W; Zheng Y; Xu H; Zhang C; He Q; Zhang L; Li Z; Zhou D
PLoS One; 2014; 9(11):e113186. PubMed ID: 25427200
[TBL] [Abstract][Full Text] [Related]
34. Acquisition of doxorubicin resistance facilitates migrating and invasive potentials of gastric cancer MKN45 cells through up-regulating aldo-keto reductase 1B10.
Morikawa Y; Kezuka C; Endo S; Ikari A; Soda M; Yamamura K; Toyooka N; El-Kabbani O; Hara A; Matsunaga T
Chem Biol Interact; 2015 Mar; 230():30-9. PubMed ID: 25686905
[TBL] [Abstract][Full Text] [Related]
35. Regulation of pancreatic cancer growth by superoxide.
Du J; Nelson ES; Simons AL; Olney KE; Moser JC; Schrock HE; Wagner BA; Buettner GR; Smith BJ; Teoh ML; Tsao MS; Cullen JJ
Mol Carcinog; 2013 Jul; 52(7):555-67. PubMed ID: 22392697
[TBL] [Abstract][Full Text] [Related]
36. Inhibiting proliferation and migration of lung cancer using small interfering RNA targeting on Aldo-keto reductase family 1 member B10.
Zhou Z; Zhao Y; Gu L; Niu X; Lu S
Mol Med Rep; 2018 Feb; 17(2):2153-2160. PubMed ID: 29207124
[TBL] [Abstract][Full Text] [Related]
37. AKR1B10, a transcriptional target of p53, is downregulated in colorectal cancers associated with poor prognosis.
Ohashi T; Idogawa M; Sasaki Y; Suzuki H; Tokino T
Mol Cancer Res; 2013 Dec; 11(12):1554-63. PubMed ID: 24140838
[TBL] [Abstract][Full Text] [Related]
38. Up-regulation of MSX2 enhances the malignant phenotype and is associated with twist 1 expression in human pancreatic cancer cells.
Satoh K; Hamada S; Kimura K; Kanno A; Hirota M; Umino J; Fujibuchi W; Masamune A; Tanaka N; Miura K; Egawa S; Motoi F; Unno M; Vonderhaar BK; Shimosegawa T
Am J Pathol; 2008 Apr; 172(4):926-39. PubMed ID: 18349132
[TBL] [Abstract][Full Text] [Related]
39. Silencing expression of ribosomal protein L26 and L29 by RNA interfering inhibits proliferation of human pancreatic cancer PANC-1 cells.
Li C; Ge M; Yin Y; Luo M; Chen D
Mol Cell Biochem; 2012 Nov; 370(1-2):127-39. PubMed ID: 22868929
[TBL] [Abstract][Full Text] [Related]
40. Rottlerin suppresses growth of human pancreatic tumors in nude mice, and pancreatic cancer cells isolated from Kras(G12D) mice.
Huang M; Tang SN; Upadhyay G; Marsh JL; Jackman CP; Srivastava RK; Shankar S
Cancer Lett; 2014 Oct; 353(1):32-40. PubMed ID: 25050737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
